CN Patent
CN114591319B — 四氢吡啶并嘧啶类衍生物及其用途
Assigned to Jiangsu Simcere Pharmaceutical Co Ltd · Expires 2024-06-28 · 2y expired
What this patent protects
本发明提供了一种式(I)所示的新型的哌嗪类化合物或其药学上可接受的盐,含有它们的药物组合物以及其在制备预防和/或治疗针对KRAS G12C突变肿瘤药物中的应用。
USPTO Abstract
本发明提供了一种式(I)所示的新型的哌嗪类化合物或其药学上可接受的盐,含有它们的药物组合物以及其在制备预防和/或治疗针对KRAS G12C突变肿瘤药物中的应用。
Drugs covered by this patent
- Krazati (ADAGRASIB) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.